Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS.

Frauke Zipp, Axel Methner

Journal: Nature reviews. Neurology 2013;9(2):72-3

PMID: 23338282

Full Text on Nature Publishing Group View on PubMed

Abstract

2012 witnessed important developments for multiple sclerosis, including successful phase III trials of novel oral therapeutics and identification of the potassium channel KIR4.1 as an autoimmune target. Additionally, the lung was highlighted as an important site for immune-cell programming, and the relevance of a TNF receptor variant was clarified.

Address: Focus Program Translational Neuroscience, Rhine Main Neuroscience Network, Johannes Gutenberg University Medical Centre Mainz, Department of Neurology, Langenbeckstrasse 1, D-55131 Mainz, Germany. [email protected]

DOI: 10.1038/nrneurol.2012.277

Link outs

Free resources

Medical:

https://medlineplus.gov/multiplesclerosis.html

Other Literature Sources:

Subscription / membership required

Full Text Sources:

https://doi.org/10.1038/nrneurol.2012.277

MeSH Terms: Clinical Trials as Topic, Dimethyl Fumarate, Fumarates, Humans, Immunosuppressive Agents, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Potassium Channels, Inwardly Rectifying, Quinolones, Receptors, Tumor Necrosis Factor, Type I, T-Lymphocytes, Kcnj10 Channel